Efficacy and safety of ozanimod from the 2-year blinded extension of RADIANCE: A randomized, double-blind, placebo-controlled Phase 2 trial in relapsing multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2016
This article has no abstract
Epistemonikos ID: c7f0b280bd629359cc64cda933487d78ad58b89c
First added on: Apr 29, 2026